RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 该项目为非人类灵长类特异性免疫相关试剂的测试、优化使用和分配提供了一个资源。因此，编码各种非人灵长类细胞因子的cDNA已经并将继续被克隆和测序。在过去的一年里，PD-1、PD-L1、PD-L2、OX40L、MIP3a、IL-17、IL-23、4-1BBL、CD24和IL-15Ra的基因和剪接变异体已被添加到旧世界NHP cDNA目录中。此外，精选的非人灵长类重组蛋白的生产一直在进行中，如rMamu RANTES、干扰素-a、干扰素-g、GM-CSF、可溶性PD1、IL-7、10和15。 在历年内，资源中心共向20名调查员提供了54种试剂。这些试剂包括33个cDNA或表达克隆、23个不同数量的细胞因子重组蛋白和1个产生rMamu IL-12B的转基因细胞。部分或全部利用这一资源进行了其他几项研究：选择钾通道阻滞剂PAP-1、Shk(L)5和TRAM-34进行体内药代动力学和生物活性测试。用IL-15和IL-7在未感染和SIV感染的恒河猴体内试验，以描述这些细胞因子对体内病毒复制和免疫反应的影响。此外，该资源还测试了煤烟曼加比体内CD4+T细胞的耗竭情况，以研究体内这种耗尽的免疫学结果，以及rIL-7治疗在该模型中恢复CD4隔室的潜在益处。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project serves as a resource for the testing, optimization of use and distribution of nonhuman primate specific immune related reagents. Therefore, cDNA coding for various nonhuman primate cytokines have been and continue to be cloned and sequenced. During the past year, the genes and splice variants for PD-1, PD-L1, PD-L2, OX40L, MIP3a, IL-17, IL-23, 4-1BBL, CD24 and IL-15Ra have been added to the catalogue of Old-World NHP cDNAs available. In addition, the production of select nonhuman primate recombinant proteins such as rMamu RANTES, IFN-a, IFN-g, GM-CSF, soluble PD1, IL-7, 10 and 15 has been ongoing. Within the calendar year, the Resource has provided a total of 54 reagents to 20 investigators. These reagents included 33 cDNA or expression clones, 23 orders of cytokine recombinant proteins in varying amounts and 1 order of transfected cell producing rMamu IL-12B. Several additional studies were done in part or fully by this resource: The pharmacokinetics and biological activity of select potassium channels blockers Pap-1, Shk(l)5 and TRAM-34 were tested in vivo. The administration of IL-15 and IL-7 in uninfected and SIV infected rhesus macaques was tested for the delineation of these cytokine's influence on viral replication and immune responses in vivo. In addition, this resource has tested the depletion of CD4+ T cells from sooty mangabeys to study the immunological outcome of such depletion in vivo, as well as the potential benefit of rIL-7 therapy in restoring the CD4 compartment in this model.